<em>Targeted Oncology</em>™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: Virtual Tumor Board on April 30. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This first one will focus on chronic lymphocytic leukemia (CLL).
“We are thrilled to introduce this educational platform for community-based oncologists,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of Targeted Oncology™. “Through this initiative, we look forward to empowering oncologists by providing them with the latest updates from their specific field of practice.”
The Virtual Tumor Board will feature multiple experts that will provide an in-depth analysis on CLL diagnosis, biomarker testing and therapeutic approaches from a collaborative medical setting. Together, these experts will provide a focused look at multiple case sets from a treatment team perspective to further educate community-based oncologists in this comprehensive series of practice-changing insights.
Key opinion leaders for this virtual tumor board are:
About Targeted Oncology
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More